Xavier Dolcet

List of Publications by Year
in descending order

78 papers	4,300 citations	109137 35 h-index	110170 64 g-index
81 all docs	81 docs citations	81 times ranked	7076 citing authors

#	Article	IF	Citations
1	Elimination of Vitamin D Signaling Causes Increased Mortality in a Model of Overactivation of the Insulin Receptor: Role of Lipid Metabolism. Nutrients, 2022, 14, 1516.	1.7	0
2	ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status. Cancers, 2021, 13, 3803.	1.7	3
3	Endometrial PTEN Deficiency Leads to SMAD2/3 Nuclear Translocation. Cancers, 2021, 13, 4990.	1.7	13
4	T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. Journal of Investigative Dermatology, 2020, 140, 1253-1265.	0.3	17
5	Involvement of the mitochondrial nuclease EndoG in the regulation of cell proliferation through the control of reactive oxygen species. Redox Biology, 2020, 37, 101736.	3.9	7
6	Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer. Gynecologic Oncology, 2019, 153, 425-435.	0.6	30
7	Cytoplasmic cyclin D1 regulates glioblastoma dissemination. Journal of Pathology, 2019, 248, 501-513.	2.1	21
8	Tumor suppressive function of E2Fâ€1 on PTENâ€induced serrated colorectal carcinogenesis. Journal of Pathology, 2019, 247, 72-85.	2.1	5
9	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy, 2017, 13, 608-624.	4.3	65
10	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	0.8	53
11	A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-Î² in mouse endometrium. Cell Death and Differentiation, 2017, 24, 1443-1458.	5.0	24
12	Palbociclib has antitumour effects on <i>Ptenâ€</i>deficient endometrial neoplasias. Journal of Pathology, 2017, 242, 152-164.	2.1	25
13	2â€phenylethynesulphonamide (PFTâ€Î¼) enhances the anticancer effect of the novel hsp90 inhibitor NVPâ€AUY922 in melanoma, by reducing GSH levels. Pigment Cell and Melanoma Research, 2016, 29, 352-371.	1.5	11
14	Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin. Nature Communications, 2016, 7, 11581.	5.8	92
15	Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies. Blood, 2016, 127, 1907-1911.	0.6	7
16	Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. European Journal of Cancer, 2016, 63, 74-87.	1.3	13
17	Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 526-535.	1.8	6
18	Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-ÎºB Pathway in Endometrial Cancer. Molecular Imaging and Biology, 2016, 18, 545-556.	1.3	9

#	Article	IF	Citations
19	Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer. Oncotarget, 2016, 7, 26979-26991.	0.8	39
20	Annexinâ€A2 as predictor biomarker of recurrent disease in endometrial cancer. International Journal of Cancer, 2015, 136, 1863-1873.	2.3	39
21	Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: Endometrial cancer as a model. Methods, 2015, 77-78, 31-40.	1.9	12
22	Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. PLoS ONE, 2015, 10, e0136863.	1.1	51
23	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. Molecular Cancer, 2014, 13, 223.	7.9	88
24	FISH analysis of PTEN in endometrial carcinoma. comparison with SNP arrays and MLPA. Histopathology, 2014, 65, 371-388.	1.6	3
25	Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Human Pathology, 2014, 45, 522-532.	1.1	36
26	ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas. Carcinogenesis, 2014, 35, 2679-2686.	1.3	30
27	Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma. Laboratory Investigation, 2014, 94, 608-622.	1.7	27
28	Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 776-787.	1.9	12
29	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. Human Pathology, 2014, 45, 2394-2403.	1.1	18
30	Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation. PLoS ONE, 2014, 9, e92764.	1.1	3
31	Epithelial-to-mesenchymal transition and stem cells in endometrial cancer. Human Pathology, 2013, 44, 1973-1981.	1.1	87
32	Long-Term Estradiol Exposure Is a Direct Mitogen for Insulin/EGF-Primed Endometrial Cells and Drives PTEN Loss-Induced Hyperplasic Growth. American Journal of Pathology, 2013, 183, 277-287.	1.9	22
33	Combination of Vorinostat and caspaseâ€8 inhibition exhibits high antiâ€tumoral activity on endometrial cancer cells. Molecular Oncology, 2013, 7, 763-775.	2.1	16
34	An inducible knock-out mouse to model cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias. DMM Disease Models and Mechanisms, 2013, 6, 710-20.	1.2	38
35	Three-dimensional epithelial cultures: a tool to model cancer development and progression. Histology and Histopathology, 2013, 28, 1245-56.	0.5	10
36	ERÎ±-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a critical role for TNFÎ± and IL1Î± in lumen formation and maintenance.. Journal of Cell Science, 2012, 125, 1929-44.	1.2	11

#	Article	IF	Citations
37	Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Human Pathology, 2012, 43, 632-643.	1.1	75
38	Blockade of NFÎºB activity by Sunitinib increases cell death in Bortezomibâ€treated endometrial carcinoma cells. Molecular Oncology, 2012, 6, 530-541.	2.1	29
39	The EMT signaling pathways in endometrial carcinoma. Clinical and Translational Oncology, 2012, 14, 715-720.	1.2	95
40	Immunohistochemical features of postâ€radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia. Histopathology, 2012, 60, 460-471.	1.6	12
41	Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. International Journal of Cancer, 2012, 130, 967-978.	2.3	35
42	ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells. International Journal of Cancer, 2012, 130, 1532-1543.	2.3	50
43	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. American Journal of Pathology, 2011, 178, 1529-1543.	1.9	30
44	Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma. Human Pathology, 2011, 42, 185-193.	1.1	38
45	Stem Cells in Human Endometrium and Endometrial Carcinoma. International Journal of Gynecological Pathology, 2011, 30, 317-327.	0.9	26
46	Nuclear factor-ÎºB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1Î± independent manner. Laboratory Investigation, 2011, 91, 859-871.	1.7	33
47	FGFR2 alterations in endometrial carcinoma. Modern Pathology, 2011, 24, 1500-1510.	2.9	63
48	The Canonical Nuclear Factor-ÂB Pathway Regulates Cell Survival in a Developmental Model of Spinal Cord Motoneurons. Journal of Neuroscience, 2011, 31, 6493-6503.	1.7	26
49	DcR1 expression in endometrial carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 39-44.	1.4	11
50	A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis. American Journal of Pathology, 2010, 176, 2722-2731.	1.9	46
51	Loss of Sprouty1 Rescues Renal Agenesis Caused by Ret Mutation. Journal of the American Society of Nephrology: JASN, 2009, 20, 255-259.	3.0	45
52	Subtractive Proteomic Approach to the Endometrial Carcinoma Invasion Front. Journal of Proteome Research, 2009, 8, 4676-4684.	1.8	22
53	1,25-Dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis, 2009, 204, 85-89.	0.4	151
54	CK2Î² Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation. American Journal of Pathology, 2009, 174, 287-296.	1.9	42

#	Article	IF	Citations
55	A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma. , 2009, 31, 217-26.		6
56	Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Modern Pathology, 2008, 21, 691-699.	2.9	71
57	Nuclear factorâ€"Î°B activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Human Pathology, 2008, 39, 994-1001.	1.1	25
58	Targeted therapies in gynecologic cancers and melanoma. Seminars in Diagnostic Pathology, 2008, 25, 262-273.	1.0	8
59	Loss of Heterozygosity in Endometrial Carcinoma. International Journal of Gynecological Pathology, 2008, 27, 305-317.	0.9	18
60	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anti-Cancer Drugs, 2008, 19, 115-124.	0.7	51
61	Nuevas dianas terapÃ©uticas en el melanoma. Piel, 2007, 22, 205-211.	0.0	0
62	PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterationsâ˜†. Human Pathology, 2006, 37, 1465-1472.	1.1	134
63	Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma Research, 2006, 16, 127-135.	0.6	14
64	Proteasome Inhibitors Induce Death but Activate NF-Î°B on Endometrial Carcinoma Cell Lines and Primary Culture Explants. Journal of Biological Chemistry, 2006, 281, 22118-22130.	1.6	94
65	Survivin Expression in Endometrial Carcinoma:. International Journal of Gynecological Pathology, 2005, 24, 247-253.	0.9	62
66	FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Laboratory Investigation, 2005, 85, 885-894.	1.7	59
67	Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Modern Pathology, 2005, 18, 719-727.	2.9	110
68	NF-kB in development and progression of human cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 475-482.	1.4	926
69	The Contribution of Apoptosis-inducing Factor, Caspase-activated DNase, and Inhibitor of Caspase-activated DNase to the Nuclear Phenotype and DNA Degradation during Apoptosis. Journal of Biological Chemistry, 2005, 280, 35670-35683.	1.6	80
70	NF-Î°B signalling regulates the growth of neural processes in the developing PNS and CNS. Development (Cambridge), 2005, 132, 1713-1726.	1.2	148
71	The death receptor antagonist FAIM promotes neurite outgrowth by a mechanism that depends on ERK and NF-Î°B signaling. Journal of Cell Biology, 2004, 167, 479-492.	2.3	75
72	HGF regulates the development of cortical pyramidal dendrites. Development (Cambridge), 2004, 131, 3717-3726.	1.2	83

#	Article	IF	Citations
73	Abnormalities in the NF-ÎºB family and related proteins in endometrial carcinoma. Journal of Pathology, 2004, 204, 569-577.	2.1	101
74	HGF promotes survival and growth of maturing sympathetic neurons by PI-3 kinase- and MAP kinase-dependent mechanisms. Molecular and Cellular Neurosciences, 2004, 27, 441-452.	1.0	59
75	Activation of Phosphatidylinositol 3-Kinase, but Not Extracellular-Regulated Kinases, Is Necessary to Mediate Brain-Derived Neurotrophic Factor-Induced Motoneuron Survival. Journal of Neurochemistry, 2002, 73, 521-531.	2.1	111
76	Cytokines Promote Motoneuron Survival through the Janus Kinase-Dependent Activation of the Phosphatidylinositol 3-Kinase Pathway. Molecular and Cellular Neurosciences, 2001, 18, 619-631.	1.0	86
77	Neuronal survival induced by neurotrophins requires calmodulin. Journal of Cell Biology, 2001, 154, 585-598.	2.3	53
78	Receptors of the Glial Cell Line-Derived Neurotrophic Factor Family of Neurotrophic Factors Signal Cell Survival through the Phosphatidylinositol 3-Kinase Pathway in Spinal Cord Motoneurons. Journal of Neuroscience, 1999, 19, 9160-9169.	1.7	153